Stay up-to-date on Laxxon's latest news + insights
In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100 Billion in sales.
Our Mission
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.
The basis of Laxxon's pharmaceutical solutions is our cutting-edge 3D screen printing technology and the extensive intellectual property surrounding it.
Our commitment to innovation and health is fueled by the expertise, integrity, agility, and diversity of the Laxxon team.
Laxxon strives to accelerate pharmaceutical progress globally by establishing ourselves as the leader in the field of 3D printed drugs.
Laxxon 3D Screen Printing Technology Enables Fabrication of Oral Drug Dosage Forms
The Future of Pharmaceuticals
Disruptive Additive Manufacturing Solutions for Partners & Patients
3D Screen Printing Technology Enables Fabrication of Oral Drug Dosage Forms with Freely Tailorable Release Profiles - International Journal of Pharmaceutics
Laxxon Medical Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Pharmaceutics 3D Screen Printing Offers Unprecedented Anticounterfeiting Strategies for Oral Solid Dosage Forms Feasible for Large Scale Production
Laxxon Announces Formation of Renowned Scientific Advisory Board
Laxxon Medical’s Scientific Advisory Board features global experts in pharmaceutical and chemical thought, application, development, material science, and regulatory research.
CSO Dr. Achim Schneeberger Discusses LXM.5, New Generation Levodopa/Carbidopa Parkinson’s Treatment
Laxxon Medical to Attend BIO International in San Diego on June 3-6
Advanced Patented Generics
Our Solutions
3D Printed Pharmaceutical Solutions for Patients
& Partners
Advanced Patented Generics, Patent Extension,
& New Drug Development
Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology.
For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients.
Laxxon is the leader of 3D screen-printed additive manufacturing in in the pharmaceutical industry, globally.
In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100 Billion in sales.
Laxxon has both an external pipeline and in-house Advanced Patented Generic pipeline.
Pipeline consists of 13 in-house products and 3 products that are being developed for external clients
All products created with our SPID®-Technology manufacturing approach are patent protected,
whether engineered in-house or with an external partner
